Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Neovasc Inc (NVCN)

Neovasc Inc (NVCN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,926
  • Shares Outstanding, K 70,655
  • Annual Sales, $ 1,750 K
  • Annual Income, $ -108,040 K
  • 60-Month Beta 1.49
  • Price/Sales 24.24
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.96
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/14/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.17
  • Number of Estimates 1
  • High Estimate -0.17
  • Low Estimate -0.17
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.46 +33.35%
on 06/11/19
0.68 -9.53%
on 06/26/19
+0.11 (+20.75%)
since 05/24/19
3-Month
0.37 +64.89%
on 03/28/19
0.85 -27.41%
on 05/23/19
+0.20 (+49.61%)
since 03/26/19
52-Week
0.37 +64.89%
on 03/28/19
4.58 -86.61%
on 10/10/18
-3.39 (-84.67%)
since 06/26/18

Most Recent Stories

More News
Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule

NASDAQ, TSX: NVCN

NVCN : 0.61 (-5.63%)
NVCN.TO : 0.82 (-3.53%)
Neovasc Announces Nasdaq Continuing to Monitor Minimum Market Value Deficiency Following 10 Consecutive Business Days Above US$35 Million

NASDAQ, TSX: NVCN

NVCN : 0.61 (-5.63%)
Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders and Provides Update on Neovasc Reducer™

NASDAQ, TSX: NVCN

NVCN : 0.61 (-5.63%)
Neovasc Announces Positive Two-Year Follow-up Safety and Efficacy Data for the Neovasc Reducer(TM) in a Peer Reviewed Article in the International Journal of Cardiology

NASDAQ, TSX: NVCN

NVCN : 0.61 (-5.63%)
NVCN.TO : 0.82 (-3.53%)
Neovasc Announces Closing of Private Placement of Convertible Debt and Common Shares for Gross Proceeds of US$11.5 Million

NASDAQ, TSX: NVCN

NVCN : 0.61 (-5.63%)
NVCN.TO : 0.82 (-3.53%)
/C O R R E C T I O N from Source -- Neovasc Inc./

The news release, Neovasc Announces First Quarter 2019 Financial Results, published at 4:00 p.m. ET on May 9, 2019 inadvertently included a statement that the Company had announced a financing. No such...

NVCN : 0.61 (-5.63%)
Neovasc Announces Treatment of 1,000th Refractory Angina Patient with Neovasc Reducer™

NASDAQ, TSX: NVCN

NVCN : 0.61 (-5.63%)
NVCN.TO : 0.82 (-3.53%)
Neovasc Provides Highlights from Annual Conference of the DGK, the German Society of Cardiology; Symposium Generates Growing Support for Reducer

NASDAQ, TSX: NVCN

NVCN : 0.61 (-5.63%)
NVCN.TO : 0.82 (-3.53%)
Neovasc Announces Resolution of Last Remaining Active Litigation

NASDAQ, TSX: NVCN

EW : 187.05 (-2.56%)
NVCN : 0.61 (-5.63%)
NVCN.TO : 0.82 (-3.53%)
Neovasc Announces Peer Reviewed Publication in the International Journal of Cardiology Demonstrating that the Neovasc Reducer Improves Diastolic Function in patients suffering from severe angina

NASDAQ, TSX: NVCN

NVCN : 0.61 (-5.63%)
NVCN.TO : 0.82 (-3.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade NVCN with:

Business Summary

Neovasc Inc. is a specialty medical device company. It develops, manufactures and markets products for the cardiovascular marketplace. The Company's products include the Tiara (TM) mitral valve prosthesis in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer (TM)...

See More

Key Turning Points

2nd Resistance Point 0.74
1st Resistance Point 0.67
Last Price 0.61
1st Support Level 0.56
2nd Support Level 0.50

See More

52-Week High 4.58
Fibonacci 61.8% 2.97
Fibonacci 50% 2.48
Fibonacci 38.2% 1.98
Last Price 0.61
52-Week Low 0.37

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar